Evidence map›Paper›PMID 35534652›Full record

ArticleAAPS PharmSciTech2022

Pharmacotechnical Evaluation by SeDeM Expert System to Develop Orodispersible Tablets.

Monica R P Rao, Sharwari Sapate, Ashwini Sonawane

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. ROS-Induced DNA-Damage and Autophagy in Oral Squamous Cell Carcinoma byInternational journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Monica R P RaoDepartment of Pharmaceutics, AISSMS College of Pharmacy, Kennedy Road, Near R.T.O., Pune, 411001, India. monicarp_6@hotmail.com.
Sharwari SapateDepartment of Pharmaceutics, AISSMS College of Pharmacy, Kennedy Road, Near R.T.O., Pune, 411001, India.
Ashwini SonawaneDepartment of Pharmaceutics, AISSMS College of Pharmacy, Kennedy Road, Near R.T.O., Pune, 411001, India.
Savitribai Phule Pune University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sediment delivery model (SeDeM) system is innovative tool to correlate micromeritic properties of powders with compressibility. It involves computation of indices which facilitate direct compressibility of solids and enable corrective measures through particle engineering. Study had multiple objectives, viz, (i) to enhance solubility of BCS class II, nevirapine using solid dispersions; (ii) SeDeM analyses of excipients and solid dispersions to analyze direct compressibility; and (iii) prepare orodispersible tablets (ODT). Solid dispersions were prepared by solvent evaporation. Superdisintegrants and solid dispersions were analyzed for primary indices of dimension, compressibility, flowability, stability, and disgregability derived from micromeritic properties. Radar diagrams were constructed to provide visual clues to deficient properties for direct compressibility. ODTs were prepared using excipients which passed criteria for direct compressibility and evaluated for tablet properties. Solid dispersions with Eudragit S100 revealed 6 to 10 fold increase in solubility in various dissolution media including biorelevant media in comparison with plain drug. Solubility was found to be pH dependent. SeDeM analyses facilitated identification of superdisintegrants and excipients with unfavorable compressibility. Radar diagrams provided a clear pictorial evidence of lacunae in powder properties. Based on SeDeM results, tablets were formulated by direct compression using crosspovidone, croscarmellose sodium, and mannitol. All batches showed 40% release in first minute in simulated salivary fluid.

Indexed as

ExcipientsExpert SystemsDrug CompoundingPowdersSolubilityTabletsExcipientsPowdersTabletsantiretroviralsmicromeriticsnevirapineorodispersibleSeDeMsuperdisintegrants

Identifiers

PMID35534652
OpenAlexW4229450400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.